title: Therapy of recurrent high-grade gliomas with surgery, autologous mitogen-activated IL-2-stimulated (MAK) killer lymphocytes, and rIL-2: II. Correlation of survival with MAK cell tumor necrosis factor production in vitro.
abstract: Seven patients with recurrent high-grade glioma were treated in a Phase I/II trial with surgical debulking, after which mitogen-activated IL-2-stimulated killer (MAK) lymphocytes and 10(5) units rIL-2 were implanted in the surgical defect. The therapy was well tolerated, and the mean survival of this group of patients was 29 weeks. Tumor necrosis factor (TNF) production by MAK lymphocytes stimulated with IL-2 in vitro was measured. A significant (r = .78, p = .04) correlation between survival of patients after therapy and the ability of the MAK lymphocytes to produce TNF in vitro was noted. A significant negative correlation (r = -.82, p = .02) was found when comparing TNF production and increasing tumor size measured on MRI. No correlation was found between TNF production in vitro and MAK lymphocytes lytic activity on K562 and U373 target cells. No correlation was found between survival and MAK cell lytic activity measured on K562 and U373 target cells. We conclude that TNF production in vitro and cytotoxic activity measured in vitro are measures of different antitumor activity in vivo and in vitro. TNF production during IL-2-stimulated proliferation may be an important in vitro assay in terms of predicting length of survival of recurrent high-grade gliomas.
authors.affiliation: Department of Dermatology, V.A., Long Beach, CA 90822.
authors.forename: E W
authors.initials: EW
authors.lastname: Jeffes
authors.forename: Y B
authors.initials: YB
authors.lastname: Beamer
authors.forename: S
authors.initials: S
authors.lastname: Jacques
authors.forename: J S
authors.initials: JS
authors.lastname: Coss
authors.forename: R L
authors.initials: RL
authors.lastname: Nep
authors.forename: M
authors.initials: M
authors.lastname: Beckman
authors.forename: R S
authors.initials: RS
authors.lastname: Yamamoto
authors.forename: G
authors.initials: G
authors.lastname: Granger
mesh_terms: D000328:Adult; D002860:Chromium Radioisotopes; D003131:Combined Modality Therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005910:Glioma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007376:Interleukin-2 / Q000627:therapeutic use*; D015979:Killer Cells, Lymphokine-Activated / Q000187:drug effects / Q000378:metabolism / Q000637:transplantation*; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D010835:Phytohemagglutinins / Q000494:pharmacology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D015996:Survival Rate; D014182:Transplantation, Autologous; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis*
chemical_list: D002860:Chromium Radioisotopes; D007376:Interleukin-2; D010835:Phytohemagglutinins; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha